Utpal Koppikar
Director/Board Member bij C4 THERAPEUTICS, INC.
Vermogen: 172 592 $ op 31-03-2024
Profiel
Utpal Koppikar is an Independent Director at C4 Therapeutics, Inc. He previously worked as a Director at Flexion Therapeutics, Inc. and as Vice President-Corporate & Operations Finance at Gilead Sciences, Inc. He is also the Chief Financial Officer & Senior Vice President at Atara Biotherapeutics, Inc. Mr. Koppikar holds a graduate degree from Stanford University, an undergraduate degree from the University of Maryland, and an MBA from UCLA Anderson School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 02-03-2023 | 181 978 ( 0.14% ) | 126 293 $ | 31-03-2024 | |
C4 THERAPEUTICS, INC.
0.01% | 15-06-2023 | 5 667 ( 0.01% ) | 46 299 $ | 31-03-2024 |
Actieve functies van Utpal Koppikar
| Bedrijven | Functie | Begin |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 16-03-2022 |
Eerdere bekende functies van Utpal Koppikar
| Bedrijven | Functie | Einde |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31-03-2023 |
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19-11-2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-06-2018 |
Opleiding van Utpal Koppikar
| Stanford University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
